Compass Therapeutics to Commence Trading on the OTCQB Venture Market Under the Symbol “CMPX”
Compass Therapeutics, Inc. (OTCQB: CMPX) has announced that its common stock shares have been approved for trading on the OTCQB Venture Market in the U.S., effective March 5, 2021. The company specializes in developing proprietary antibody therapeutics aimed at treating solid tumors and hematological malignancies. Its lead candidate, CTX-471, is currently in a Phase 1 clinical study targeting patients who have relapsed after PD-1/PD-L1 treatment. The company operates from Boston, MA, and focuses on engaging the immune system through its innovative platforms.
- Shares cleared for trading on OTCQB, increasing visibility and liquidity.
- Development of proprietary therapeutic platforms such as StitchMabs™.
- Lead candidate CTX-471 currently in Phase 1 clinical study.
- Dependence on additional funding for business and product development.
Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, announced today that shares of the company’s common stock have been cleared for trading on the OTCQB Venture Market in the United States. The Company’s shares will trade under the ticker symbol "CMPX", effective at the market open on March 5, 2021.
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, and is currently being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company’s offices and labs are located in Boston, MA. Its website is at www.compasstherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the commencement of trading on OTCQB, references to our product candidates and the development and therapeutic potential thereof, our technologies for identifying additional product candidates, and our business and development plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, our ability to identify additional product candidates for development, our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, and competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation our Form 10-Q for the quarter ended September 30, 2020, and our subsequent filings with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006114/en/
FAQ
When will CMPX begin trading on OTCQB?
What is the primary focus of Compass Therapeutics?
What is the lead product candidate of CMPX?
Where is Compass Therapeutics located?
Why does CMPX depend on additional funding?
